Salix Pharmaceuticals To Share New Data At Digestive Disease Week 2022

LAVAL, Quebec - Bausch Health Companies Inc. (NYSE/TSX: BHC) ('Bausch Health') and its gastroenterology business, Salix Pharmaceuticals, ('Salix'), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, announced seven posters on behalf of XIFAXAN (rifaximin), TRULANCE (plecanatide) and PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week (DDW) 2022, which is being held virtually and in-person in San Diego, Calif., from May 21-24, 2022. The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022.

The full list of Salix research to be featured at DDW 2022 is as follows:

XIFAXAN

Bajaj, Jasmohan S. et al. 'Rifaximin Plus Lactulose is More Efficacious than Lactulose Alone for Risk Reduction of Overt Hepatic Encephalopathy Recurrence: A Subgroup Analysis by Viral or Alcohol Cirrhosis Etiology'

Lacy, Brian et al. 'A New Trisymptom Composite Endpoint to Evaluate the Efficacy of Rifaximin for the Multiple Symptoms of Irritable Bowel Syndrome with Diarrhea (IBS-D): A Pooled Analysis of Two Randomized Phase 3 Trials'

TRULANCE

Shah, Eric et al. 'Plecanatide Produces A More Rapid and Sustained Clinical Response Compared to Placebo in Patients with Irritable Bowel Syndrome with Constipation'

PLENVU

Brooks, D. Cash et al. 'Low Risk of Hypokalemia in Adults Treated with the 1 Liter Polyethylene Glycol-Based Bowel Preparation NER1006: A Pooled Analysis of Two Randomized Phase 3 Trials'

Epstein, Michael S. et al. 'NER1006, A 1 Liter Polyethylene Glycol-Based Bowel Preparation, is an Independent Predictor of Adequate and High-Quality Cleansing Success in Adults Undergoing Colonoscopy: A Pooled Analysis of Two Randomized Phase 3 Trials'

Epstein, Michael S. et al. 'Same-Day Morning-Only Dosing Of 1 Liter NER1006, A Polyethylene Glycol Bowel Preparation, Nearly Doubles the Chance of High-Quality Cleansing Versus Standard 2 Liter Polyethylene Glycol and Ascorbate'

Poppers, David et al. 'Asymmetrically Dosed 1 Liter Polyethylene Glycol Bowel Preparation Plus Ascorbic Acid Demonstrates High-Quality Cleansing Efficacy Compared with Comparator Solutions Across Clinical Trials'

About XIFAXAN

XIFAXAN (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.

In clinical studies, the most common adverse reactions for XIFAXAN were:

HE (?10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)

IBS-D (?2%): Nausea (3%), ALT increased (2%)

INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.

XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About TRULANCE TRULANCE (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our 90% ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words 'anticipates,' 'hopes,' 'expects,' 'intends,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'believes,' 'estimates,' 'potential,' 'target,' or 'continue' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health Companies Inc.'s (Bausch Health) most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration, and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Contact:

Christina Cheng

E: [e-mail]

T: [phone]

Lainie Keller

E: [e-mail]

T: [phone]

TOLL FREE: [phone]

(C) 2022 Electronic News Publishing, source ENP Newswire